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Summary
Breast cancer is most common cancer in women. After surgical treatment and adjuvant therapy, locoregional recur-
rences do occur in certain number of patients. Herein we report a breast cancer patient who developed isolated chest wall 
local recurrence 3 years after mastectomy which was reappearing in next fi ve consecutive years. Multimodal treatment 
which includes surgical excision and adjuvant chemoradiotherapy can achieve a signifi cant degree of palliation when lo-
coregional recurrences are diagnosed. In our case, inclusion of adjuvant treatment did not provide satisfactory local control 
of disease therefore repetitive surgical excision was the only modality which off ered our patient 7 years of overall survival 
after fi rst excision of local recurrence.
KEY WORDS: breast cancer, locoregional recurrence, surgery
PRIKAZ SLUČAJA BOLESNICE S POJAVOM LOKALNOG RECIDIVA NA PRSNOM KOŠU 
PET UZASTOPNIH GODINA NAKON RADIKALNE MASTEKTOMIJE
Sažetak
Rak dojke je najčešći rak u žena. Unatoč kirurškom liječenju i adjuvantnoj terapiji, lokalni recidivi se javljaju u određe-
nom broju pacijenata. Prikazan je slučaj bolesnice s pojavama lokalnog recidiva na prsnom košu u razdoblju od pet uzasto-
pnih godina nakon radikalne mastektomije. Koristeći se multimodalnim tretmanom koji uključuje kirurški zahvat i kemo-
radioterapiju, načelno se postižu dobri rezultati u liječenju lokoregionalnog recidiva. Unatoč danoj terapiji, uzastopne kirur-
ške ekscizije su se pokazale kao jedini modalitet liječenja koji je bolesnici omogućio sedmogodišnje preživljenje nakon 
pojave prvog lokalnog recidiva.
KLJUČNE RIJEČI: rak dojke, lokalni povrat bolesti, kirurgija
INTRODUCTION
Locoregional recurrences (LRR) may occur in 
certain number of patients after primary therapy 
despite radical surgical treatment of primary 
breast cancer and adjuvant systemic therapy with 
irradiation. Most of LRR recurrences occur in the 
chest wall within 5 years of surgery. LRR are more 
frequent among high-risk patients receiving no 
postmastectomy radiotherapy (1). Here we will 
report an unusual case of a 65 year old female 
breast cancer patient treated with radical mastec-
tomy who developed isolated chest wall local re-
currence 3 years after mastectomy in the period of 




A 65-year-old postmenopausal patient had 
undergone modifi ed radical mastectomy and axil-
lar lymphadenectomy for stage I left breast cancer 
in April 2006. Final histopathological examination 
of the specimen revealed a 2,7 cm invasive ductal 
carcinoma of the left breast with no metastasis in 
axillary lymph nodes (T2, N0, M0). Immunohisto-
chemical (IHC) staining of tumor cells showed 
positive both estrogen (ER) and progesterone 
(PgR) receptors, weak membrane staining of HER-
2 and Ki-67 proliferative index of 1,5 %. The pa-
tient received postoperative adjuvant hormone 
(aromasine) therapy. Until the beginning of 2009, 
the patient was under regular follow up every six 
months and there were no signs of any local, lo-
coregional or distant recurrences. In September 
2009, a 11mm subcutaneous nodule was found at 
the center of the left chest wall mastectomy scar. 
She was referred to te hospital where fi ne needle 
aspiration (FNA) was performed. Cytological 
fi ndings revealed breast cancer metastases.  A CT 
scan of the chest and abdomen was done and no 
other regional or distant metastases were found. A 
wide local excision was performed and pathologi-
cal examination confi rmed metastatic adenocarci-
noma as it is shown in Table 1. Based on these 
fi ndings, she was administered the chest wall ir-
radiation (40Gy in 15 fractions) with a 9 MeV elec-
tron boost (10 Gy in 5 fractions) to the site of exci-
sion. During 2010 another excision was done and 
fi nal pathological examination confi rmed meta-
static adenocarcinoma of the skin and metastatic 
subcutaneous nodule. In 2011 two additional pro-
cedures were performed after patient was pre-
sented with another suspicious lesions on skin 
and after 6 months period with another nodule in 
subcutaneous region in thoracic area. Final patho-
logical examination is shown in Table 1.  During 
2012 patient presented with another skin metasta-
sis and surgical excision was performed followed 
with administration of CMF chemotherapy proto-
col and exemestan was changed to letrosole. Dur-
ing 2013 another excision was performed because 
patient presented with metastatic nodule in tho-
racic area. In the period of another two years, there 
were no signs of any other local or distant metas-
tases.
DISCUSSION
Local recurrence after primary treatment of 
breast cancer include a diverse group of lesions 
with various prognosis. Patients with chest wall 
recurrences and regional nodal involvement after 
traditional radical surgery can still achieve a sig-
nifi cant degree of palliation and even long-term 
survival with carefully harmonized multimodal 
treatment (2-4). More than half of patients with 
chest-wall-only recurrences present with solitary 
nodules and the remainder have more than one 
nodule or diff use chest wall disease. Risk factors 
for loco-regional failure following mastectomy 
can be divided into clinical, pathological, and 
treatment-related categories. Young age (<35 
years), nodal status, tumor size (> 3 cm), lympho-
vascular invasion, multicentricity, the disease free 
interval (< 2 years) and high histological grade are 
all risk factors for postmastectomy recurrence (5-
7). Other studies suggest that the molecular sub-
type may also impact local recurrence, with both 
triple negative estrogen receptor (ER) progester-
Table 1.
PATHOLOGICAL EXAMINATION OF PRIMARY BREAST CANCER AND METASTATIC CANCER





2006 Carcinoma invasivum ductale (T2,N0,M0) 27x13 90 60 neg 1,5
2009 Carcinoma metastaticum cutis 11x8 100 50 neg 27,1




100 60 neg 25
2011 Carcinoma metastaticum cutis 10,15,5 100 60 neg 26,3
2011 Carcinoma metastaticum subcutis 25x15 100 60 neg 25,5
2012 Carcinoma metastaticum cutis 20x10 95 65 neg 52
2013 Carcinoma metastaticum 10x6 100 100 neg 40
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one receptor (PR) and HER-2-neu negative sub-
types associated with a higher rate of local and 
regional relapse (8-11). There is a high risk (> 50%) 
of subsequent distant metastases following a clini-
cally isolated chest wall recurrence after initial 
mastectomy (12-13).  Options for treatment of LR 
following mastectomy include surgery, RT, che-
motherapy, hormonal therapy, or a combination 
of modalities. Patients experiencing LR after mas-
tectomy should undergo a workup for excluding 
metastatic disease. When possible, surgical exci-
sion followed by RT to the involved chest wall and 
regional lymphatics is the standard treatment ap-
proach. Systemic therapy should be considered 
for most patients following treatment of a clini-
cally isolated chest wall recurrence.
In this case report, we describe a rare case of 
fi ve consecutive years of local chest wall recur-
rences of breast carcinoma after mastectomy. Our 
patient was initially diagnosed with hormone 
positive and Her-2-negative breast cancer.  A re-
evaluation of the metastatic disease showed iden-
tical IHC phenotypes as a primary breast cancer 
even though some studies found a greater propor-
tion of conversion of ER and PR positivity in pri-
mary tumors to negative status in recurrences for 
women who received hormonal treatment.  Hor-
mone receptor heterogeneity within the same tu-
mor mass has been reported. These ER– or PR– 
metastatic tumors display much aggressive course 
after loss of hormone receptors compared with 
those retaining them, which is usually followed 
with decreased OS (9-10). The discordance be-
tween HER-2 status in primary tumors and in 
metastatic sites occurs less frequently than the dis-
cordance between hormonal receptors (8). A de-
tailed analysis of the failures occurring in the pa-
tients treated with radiotherapy, with or without 
surgery, showed that most of the failures were 
due to inadequate doses of irradiation, the use of 
fi elds that were too narrow and primary resistance 
to radiotherapy (15). Some patients have an early 
recurrence even though they had a stage I tumor 
with good prognostic features. These recurrences 
have been explained by the existence of certain 
cellular characteristics at the molecular level that 
make the tumor cells resistant to therapy (16).  Fol-
lowing LRR,  5 year overall survival and distant 
metastasis free survival were 70% and 65% for late 
chest wall relapse compared to 47% and 42% for 
early chest wall relapse as showed by Morane et al 
(14). Our patient falls in the category of early chest 
wall relapse and despite received irradiation ther-
apy and adjuvant chemotherapeutic protocol in 
the period of fi ve years after fi rst local recurrence 
was discovered, wide surgical local excision pro-
vided as good or even bett er local control than any 
other treatment modalities with excellent OS of 7 
years after fi rst LRR was discovered.
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